JP5903438B2 - 多発性硬化症（ｍｓ）の新規の治療 - Google Patents

多発性硬化症（ｍｓ）の新規の治療 Download PDF

Info

Publication number
JP5903438B2
JP5903438B2 JP2013537131A JP2013537131A JP5903438B2 JP 5903438 B2 JP5903438 B2 JP 5903438B2 JP 2013537131 A JP2013537131 A JP 2013537131A JP 2013537131 A JP2013537131 A JP 2013537131A JP 5903438 B2 JP5903438 B2 JP 5903438B2
Authority
JP
Japan
Prior art keywords
flurbiprofen
treatment
multiple sclerosis
coo
eae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013537131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014505015A5 (OSRAM
JP2014505015A (ja
Inventor
テゲダー，イルムガルト
ガイスリンガー，ゲルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Original Assignee
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV filed Critical Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Publication of JP2014505015A publication Critical patent/JP2014505015A/ja
Publication of JP2014505015A5 publication Critical patent/JP2014505015A5/ja
Application granted granted Critical
Publication of JP5903438B2 publication Critical patent/JP5903438B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2013537131A 2010-11-03 2011-11-03 多発性硬化症（ｍｓ）の新規の治療 Expired - Fee Related JP5903438B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1018519.7A GB2485169A (en) 2010-11-03 2010-11-03 (R)-flurbiprofen for use in the treatment of multiple sclerosis
GB1018519.7 2010-11-03
PCT/EP2011/069319 WO2012059541A1 (en) 2010-11-03 2011-11-03 Novel treatment of multiple sclerosis (ms)

Publications (3)

Publication Number Publication Date
JP2014505015A JP2014505015A (ja) 2014-02-27
JP2014505015A5 JP2014505015A5 (OSRAM) 2014-10-23
JP5903438B2 true JP5903438B2 (ja) 2016-04-13

Family

ID=43401688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537131A Expired - Fee Related JP5903438B2 (ja) 2010-11-03 2011-11-03 多発性硬化症（ｍｓ）の新規の治療

Country Status (10)

Country Link
US (1) US20130309199A1 (OSRAM)
EP (1) EP2635271A1 (OSRAM)
JP (1) JP5903438B2 (OSRAM)
KR (1) KR101877587B1 (OSRAM)
CN (1) CN103209692A (OSRAM)
BR (1) BR112013010883A2 (OSRAM)
CA (1) CA2816911C (OSRAM)
GB (1) GB2485169A (OSRAM)
RU (1) RU2595861C2 (OSRAM)
WO (1) WO2012059541A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017080989A1 (en) 2015-11-09 2017-05-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (r)-fluriprofen for the prevention and/or treatment of diabetes
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
SMT202500136T1 (it) 2016-08-31 2025-05-12 Mapi Pharma Ltd Sistemi a deposito comprendenti glatiramer acetato
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
CA3082108A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
US11498904B2 (en) 2017-11-14 2022-11-15 Merck Sharp & Dohme Llc Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
EA035792B1 (ru) * 2018-06-21 2020-08-11 Государственное Научное Учреждение "Институт Биоорганической Химии Национальной Академии Наук Беларуси" Лекарственное средство пролонгированного действия для лечения рассеянного склероза (варианты)
WO2022089598A1 (zh) * 2020-10-30 2022-05-05 杭州拉林智能科技有限公司 黄酮苷-有机胺类神经激动剂复盐化合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
JP2006517925A (ja) * 2003-01-14 2006-08-03 メルク　エンド　カムパニー　インコーポレーテッド Ａβ４２低下薬としてのジェミナル二置換ＮＳＡＩＤ誘導体
WO2008036733A2 (en) * 2006-09-19 2008-03-27 Myriad Genetics, Inc. Methods for treatment of vesicle transport disorders
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
US20090162421A1 (en) * 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
CA2710318A1 (en) * 2007-12-21 2009-07-09 Paz Arzneimittel-Entwicklungsgesellscaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
WO2011131661A1 (en) * 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis

Also Published As

Publication number Publication date
WO2012059541A1 (en) 2012-05-10
RU2013125470A (ru) 2014-12-10
RU2595861C2 (ru) 2016-08-27
US20130309199A1 (en) 2013-11-21
EP2635271A1 (en) 2013-09-11
BR112013010883A2 (pt) 2016-09-13
CN103209692A (zh) 2013-07-17
GB201018519D0 (en) 2010-12-15
KR20140017494A (ko) 2014-02-11
CA2816911A1 (en) 2012-05-10
JP2014505015A (ja) 2014-02-27
KR101877587B1 (ko) 2018-07-11
CA2816911C (en) 2018-09-25
GB2485169A (en) 2012-05-09

Similar Documents

Publication Publication Date Title
JP5903438B2 (ja) 多発性硬化症（ｍｓ）の新規の治療
US11690832B2 (en) Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
JP6169644B2 (ja) 低頻度酢酸グラチラマー治療
KR20130036217A (ko) 라퀴니모드를 이용한 루푸스 관절염의 치료
IL294736A (en) Preparations including 15-hydroxy-eicosapentaenoic acid and methods of using them
Mangoni et al. A PPAR gamma agonist protects against oral mucositis induced by irradiation in a murine model
WO2015105757A1 (en) Dimethyl fumarate for treating multiple sclerosis
AU2005200244A1 (en) Use of Riluzole for the Treatment of Multiple Sclerosis
JP2003522121A (ja) 多発性硬化症の処置のためのリルゾールの使用
Gaudet et al. Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia: A single-arm, open-label, proof-of-concept study
US11850252B2 (en) Use of nor-ursodeoxycholic acid for reducing liver fat
US12083134B2 (en) Anacardic acid for neural repair
KR102906373B1 (ko) Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
HK40083031A (en) Application of rxr agonist and thyroid hormone in preparation of medicine for treating autoimmune diseases
HK40082338A (en) Application of rxr agonist and thyroid hormone in preparation of medicine for treating autoimmune diseases
HK40082335A (en) Application of rxr agonist and thyroid hormone in preparation of medicine for treating autoimmune diseases
HK40074504A (en) Treatment of autoimmune diseases with combination of rxr agonist and thyroid hormone
CA3220534A1 (en) Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
Funakoshi et al. A Novel NF-κB Inhibitor, DHMEQ, Ameliorates Inflammatory Colonic Injuries in Mice
Brown et al. M1744 An Inhibitor of Light but not Lymphotoxin β Ameliorates Colonic GVHD Induced by Transfer of Dba/2j Bone Marrow and T Cells Into B6d2f1 Mice
Lin et al. M1745 Prevention of Colonic Fibrosis by Taurine in Rats With Colitis Induced by 2, 4, 6-Trinitrobenzene Sulphonic Acid
Singh et al. M1743 Amelioration of Citrobacter rodentium Colitis by Apoe-Mimetic Peptide COG112 by Inhibition of NF-κB
Adisen et al. Successful treatment of severe discoid lupus erythematosus with azathioprine: A case report
HK1260467B (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160314

R150 Certificate of patent or registration of utility model

Ref document number: 5903438

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees